• Users Online: 376
  • Print this page
  • Email this page
ORIGINAL ARTICLE: GERIATRIC ONCOLOGY SECTION
Year : 2020  |  Volume : 3  |  Issue : 3  |  Page : 482-488

Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial


Department of Medical Oncology, Tata Memorial Hospital, Maharashtra, Homi Bhabha National Institute, Mumbai, India

Correspondence Address:
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_208_20

Get Permissions

Background: Head-and- neck squamous cell carcinoma (HNSCC) is a commonly occurring malignancy in the geriatric population. However, there is a scarcity of data regarding the efficacy and safety of concurrent chemoradiotherapy (CRT) in these patients. Objectives: We performed a post hoc analysis of a randomized study conducted at our institution to compare the outcomes and toxicities of concurrent CRT in older versus younger patients with HNSCC. Materials and Methods: The present analysis is based on a study conducted at Tata Memorial Hospital, Mumbai, India, on patients with locally advanced HNSCC, planned for radical concurrent CRT. The patients were randomized to receive cisplatin either once-a-week at a dose of 30 mg/m2 or once-in-3-weeks at a dose of 100 mg/m2. The database of this study was used for the post hoc analysis. We evaluated the differences in the demographic and clinical features, grade 3 or worse adverse events, compliance to treatment, locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) between the older (aged ≥ 60 years) and the younger patients. Results: Out of 300 patients, 283 (94.3%) comprised the younger cohort (age <60 years) and 17 (5.7%) comprised the older cohort. There was no difference in the occurrence of severe (grade 3/4) toxicities between the two groups. At a median follow-up of 22 months (range, 3–51 months), the cumulative LRC at 2 years was 67.1% and 100% for the younger and older groups, respectively (P = 0.018). The estimated median PFS in younger patients was 24.4 months (95% confidence interval, 12.5–36.3), while it was not reached in the older group (P = 0.53). The estimated median OS was 41.3 months in the younger patients but was not reached in the older group (P = 0.613). Conclusions: Cisplatin-based concurrent CRT appears to be as efficacious in carefully selected fit older patients as in younger patients; moreover, toxicities appear to be similar in both the groups.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed88    
    Printed8    
    Emailed0    
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal